The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple- …

New guideline stresses the importance of stepwise approach to SAH; symptomatic clues, diagnostic approach, decision making for treatment, merits and demerits between clipping and …

Hypervolaemia, hypertension, and haemodilution (triple-H) therapy in an intensive-care setting has been shown in some studies to improve outcome and is an accepted means of treatment, although a randomized controlled trial has never been undertaken.

Triple-H therapy and its separate components (hypervolemia, hemodilution, and hypertension) aim to increase cerebral perfusion in subarachnoid haemorrhage (SAH) patients with delayed cerebral ischemia. We systematically reviewed the literature on the effect of triple-H components on cerebral perfusion in SAH patients. Methods

Hypervolemic hypertensive hemodilution (3H-therapy) applied to patients operated on in the acute period of aneurysmal SAH was effective in increasing cardiac output, central venous pressure, systemic arterial pressure and hence cerebral perfusion with the minimum number of complications unassociated with the use of this technique.

高动力疗法：3H. Hyperdynamic therapy. 3H的理论依据 . CVS时，脑血管自动调节机制受损，脑血流量为压力依赖性，提高血压和流速将增加受累血管供血区的CBF； 静脉输注晶体、胶体，随全血容量增加，心排血量增加，缺血局部CBF增加；

如果已經發生vasospasm 目前的標準治療是給予所謂的triple-H therapy triple-H therapy指的是hypervolemia, hypertension和hemodilution 具體內容包括: 1. 積極給予輸液(以0.9% NS為主) 使CVP不低於8 mmHg 2. 給予升壓劑(以dopamine為主) 使血壓上升至病人之神經學症狀改善為止

This study concluded that combining continuous cerebrospinal drainage and intermittent intrathecal UK injection therapy is a relatively simple and effective method for symptomatic vasospasm prophylaxis in patients with aneurysmal SAH.

2022年11月30日 · Triple H therapy is an option for preventing and treating cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Although strong clinical evidence is lacking, this therapy may be appropriate for selected cases. The rationale for triple H therapy is to increase cerebral perfusion.

The combination of induced hypertension, hypervolemia, and hemodilution (triple-H therapy) is often utilized to prevent and treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). Although this paradigm has gained widespread acceptance over the past 20 years, the efficacy of triple-H therapy and its precise role in the ...